Citations

Mayo Clinic

Showing 10 of 108599 citations.

Phase III Comparison of Twice-Daily Split-Course Irradiation Versus Once-Daily Irradiation for Patients With Limited Stage Small-Cell Lung Carcinoma
Bonner, James A. , Sloan, Jeff A. , Shanahan, Thomas G., Brooks, Burke J., Marks, Randolph S., Krook, James E., Gerstner, James B., Maksymiuk, Andrew W., Levitt, Ralph, Mailliard, James A., Tazelaar, Henry D. , Hillman, Shauna L., Jett, James R., Tazelaar, Henry D.

Journal of Clinical Oncology | February 24, 2017 | Volume: 17 | Issue: 9 | Pages: 2681-2681

10.1200/jco.1999.17.9.2681 | PMID 10561342 Get It

PURPOSE: Because small-cell lung cancer is a rapidly proliferating tumor, it was hypothesized that it may be more responsive to thoracic irradiation (TI) given twice-daily than once-daily. This hypothesis was tested in a phase III trial. PATIENTS AND METHODS: Patients with limited-stage small-cell lung cancer were entered onto a phase III trial, and all patients initially received three cycles of etoposide (130 mg/m 2 × 3) and cisplatin (30 mg/m 2 × 3). Subsequently, patients who did not have progression to a distant site (other than brain) were randomized to twice-daily thoracic irradiation (TDTI) versus once-daily thoracic irradiation (ODTI) given concomitantly with two additional cycles of etoposide (100 mg/m 2 × 3) and cisplatin (30 mg/m 2 × 3). The irradiation doses were TDTI, 48 Gy in 32 fractions, with a 2.5-week break after the initial 24 Gy, and ODTI, 50.4 Gy in 28 fractions. After thoracic irradiation, the patients received a sixth cycle of etoposide/cisplatin, followed by prophylactic cranial irradiation (30 Gy/15 fractions) if they had a complete response. RESULTS: Of 311 assessable patients enrolled in the trial, 262 underwent randomization to TDTI or ODTI. There were no differences between the two treatments with respect to local-only progression rates, overall progression rates, or overall survival. The patients who received TDTI had greater esophagitis (≥ grade 3) than those who received ODTI (12.3% v 5.3%; P = .05). Although patients received thoracic irradiation encompassing the postchemotherapy volumes, only seven of 90 local failures were out of the portal of irradiation. CONCLUSION: When TI is delayed until the fourth cycle of chemotherapy, TDTI does not result in improvement in local control or survival compared with ODTI.
Asking the Obvious Questions Regarding Patient Burden
Sloan, Jeff A.

Journal of Clinical Oncology | February 24, 2017 | Volume: 20 | Issue: 1 | Pages: 4-6

10.1200/jco.2002.20.1.4 | PMID 11773146 Get It

High-Dose Samarium-153 Ethylene Diamine Tetramethylene Phosphonate: Low Toxicity of Skeletal Irradiation in Patients With Osteosarcoma and Bone Metastases
Anderson, Peter M. , Wiseman, Gregory A., Arndt, Carola A.S., Hartmann, Lynn C. , Smithson, William A., Mullan, Brian P., Dispenzieri, Angela , Bruland, Øyvind Sverre

Journal of Clinical Oncology | February 24, 2017 | Volume: 20 | Issue: 1 | Pages: 189-196

10.1200/jco.2002.20.1.189 | PMID 11773169 Get It

PURPOSE: Samarium-153 ethylene diamine tetramethylene phosphonate (153Sm-EDTMP), a bone-seeking radiopharmaceutical, provides therapeutic irradiation to osteoblastic bone metastases. Because the dose-limiting toxicity of 153Sm-EDTMP is thrombocytopenia, a dose-escalation trial using peripheral-blood progenitor cells (PBPCs) or marrow support was conducted to treat metastatic bone cancer. PATIENTS AND METHODS: Patients with locally recurrent or metastatic osteosarcoma or skeletal metastases avid on bone scan were treated with 1, 3, 4.5, 6, 12, 19, or 30 mCi/kg of 153Sm-EDTMP. RESULTS: Thirty patients were treated with 153Sm-EDTMP. Transient symptoms of hypocalcemia were seen at 30 mCi/kg. Estimates of radioisotope bound to bone surfaces and marrow radiation dose were linear with injected amount of 153Sm-EDTMP. Cytopenias also occurred in all subjects and were dose-related. At day +13 after 153Sm-EDTMP, residual whole-body radioactivity was 1% to 65% of whole-body radioactivity considered safe for PBPC infusion, 3.6 mCi. After PBPC or marrow infusion on day +14 after 153Sm-EDTMP, recovery of hematopoiesis was problematic in two patients at the 30 mCi/kg dose infused with less than 2 × 106 CD34+/kg on day +14, but not in other patients. Reduction or elimination of opiates for pain was seen in all patients. Patients had no adverse changes in appetite or performance status. CONCLUSION: 153Sm-EDTMP with PBPC support can provide bone-specific therapeutic irradiation (estimates of 39 to 241 Gy). Hematologic toxicity at 30 mCi 153Sm-EDTMP/kg requires PBPC grafts with more than 2 × 106 CD34+/kg to overcome myeloablative effects of skeletal irradiation. Nonhematologic side effects are minimal.
Overcoming Obstacles to Hospice Care: An Ethical Examination of Inertia and Inaction
Daugherty, Christopher K. , Steensma, David P.

Journal of Clinical Oncology | February 24, 2017 | Volume: 20 | Issue: 11 | Pages: 2752-2755

10.1200/jco.2002.20.11.2752 | PMID 12039940 Get It

Correction for Vasireddy et al., Mycobacterium arupense, Mycobacterium heraklionense, and a Newly Proposed Species, “Mycobacterium virginiense” sp. nov., but Not Mycobacterium nonchromogenicum, as Species of the Mycobacterium terrae Complex Causing Tenosyn
Vasireddy, Ravikiran, Vasireddy, Sruthi, Brown‐Elliott, Barbara A. , Wengenack, Nancy L. , Eke, Uzoamaka A , Benwill, Jeana L., Turenne, Christine Y. , Wallace, Richard J. , Turenne, Christine Y

Journal of Clinical Microbiology | February 23, 2017 | Volume: 55 | Issue: 3 | Pages: 985-985

10.1128/jcm.02290-16 | PMID 28232505 Get It

A longitudinal study of whole body, tissue, and cellular physiology in a mouse model of fibrosing NASH with high fidelity to the human condition
Krishnan, Anuradha, Abdullah, Tasduq Sheikh, Mounajjed, Taofic, Hartono, Stella , McConico, Andrea L., White, Thomas A. , LeBrasseur, Nathan K. , Lanza, Ian R. , Nair, Sreekumaran, Gores, Gregory, McConico, Andrea, White, Thomas, LeBrasseur, Nathan, Lanza, Ian, Nair, Sreekumaran, Charlton, Michael , Lanza, Ian R , LeBrasseur, Nathan K

American Journal of Physiology-Gastrointestinal and Liver Physiology | February 23, 2017 | Volume: 312 | Issue: 6 | Pages: G666-G680

10.1152/ajpgi.00213.2016 | PMID 28232454 Get It

The sequence of events that lead to inflammation and fibrosing nonalcoholic steatohepatitis (NASH) is incompletely understood. Hence, we investigated the chronology of whole body, tissue, and cellular events that occur during the evolution of diet-induced NASH. Male C57Bl/6 mice were assigned to a fast-food (FF; high calorie, high cholesterol, high fructose) or standard-chow (SC) diet over a period of 36 wk. Liver histology, body composition, mitochondrial respiration, metabolic rate, gene expression, and hepatic lipid content were analyzed. Insulin resistance [homeostasis model assessment-insulin resistance (HOMA-IR)] increased 10-fold after 4 wk. Fibrosing NASH was fully established by 16 wk. Total hepatic lipids increased by 4 wk and remained two- to threefold increased throughout. Hepatic triglycerides declined from sixfold increase at 8 wk to threefold increase by 36 wk. In contrast, hepatic cholesterol levels steadily increased from baseline at 8 wk to twofold by 36 wk. The hepatic immune cell population altered over time with macrophages persisting beyond 16 wk. Mitochondrial oxygen flux rates of FF mice diet were uniformly lower with all the tested substrates (13–276 pmol·s−1·ml−1 per unit citrate synthase) than SC mice (17–394 pmol·s−1·ml−1 per unit citrate synthase) and was accompanied by decreased mitochondrial:nuclear gene copy number ratios after 4 wk. Metabolic rate was lower in FF mice. Mitochondrial glutathione was significantly decreased at 24 wk in FF mice. Expression of dismutases and catalase was also decreased in FF mice. The evolution of NASH in the FF diet-induced model is multiphasic, particularly in terms of hepatic lipid composition. Insulin resistance precedes hepatic inflammation and fibrosis. Mitochondrial dysfunction and depletion occur after the histological features of NASH are apparent. Collectively, these observations provide a unique overview of the sequence of changes that coevolve with the histological evolution of NASH. NEW & NOTEWORTHY This study demonstrates in a first of kind longitudinal analysis, the evolution of nonalcoholic steatohepatitis (NASH) on a fast-food diet-induced model. Key findings include 1) hepatic lipid composition changes in a multiphasic fashion as NASH evolves; 2) insulin resistance precedes hepatic inflammation and fibrosis, answering a longstanding chicken-and-egg question regarding the relationship of insulin resistance to liver histology in NASH; and 3) mitochondrial dysfunction and depletion occur after the histological features of NASH are apparent.
Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects
Peng, Kah Whye, Federspiel, Mark J. , Russell, Stephen J. , Galanis, Evanthia , Msaouel, Pavlos , Opyrchal, Mateusz , Dispenzieri, Angela , Russell, Stephen J

Current Cancer Drug Targets | February 23, 2017 | Volume: 18 | Issue: 2 | Pages: 177-187

10.2174/1568009617666170222125035 | PMID 28228086 Get It

Attenuated Edmonston lineage measles virus (MV-Edm) vaccine strains can preferentially infect and lyse a wide variety of cancer cells. Oncolytic MV-Edm derivatives are genetically engineered to express the human carcinoembryonic antigen (MV-CEA virus) or the human sodium iodide symporter (MV-NIS virus) and are currently being tested in clinical trials against ovarian cancer, glioblastoma multiforme, multiple myeloma, mesothelioma, head and neck cancer, breast cancer and malignant peripheral nerve sheath tumors. This review describes the basic and preclinical data that facilitated the clinical translation of MV-Edm strains, and summarizes the clinical results of this oncolytic platform to date. Furthermore, we discuss the latest clinically relevant MV-Edm vector developments and creative strategies for future translational steps.
Are there sex differences following treatment of left ventricular outflow tract obstruction in adults with hypertrophic cardiomyopathy?
Chahal, C. Anwar A. , Alhurani, Rabe E., Mohamed, Essa A. , Miller, Virginia M. , Murad, M. Hassan , Ahmed, Ahmed T. , Chahal, Anwar A, Murad, Mohammad Hassan, Somers, Virend K. , Murad, M Hassan , Chahal, Choudhary Anwar A

European Heart Journal - Quality of Care and Clinical Outcomes | February 23, 2017 | Volume: 3 | Issue: 3 | Pages: 249-250

10.1093/ehjqcco/qcx005 | PMID 28838090 Get It

S9900: A phase III trial of surgery alone or surgery plus preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Preliminary results
Pisters, Katherine M.W., Bunn, Paul, Crowley, John, Ginsberg, Robert J., Ellis, Peter , Meyers, Brandon M. , Marks, Randolph S., Treat, Joseph, Gandara, D., Vallières, Eric , Gandara, David R.

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: LBA7012-LBA7012

10.1200/jco.2005.23.16_suppl.lba7012 Get It

DNA ploidy is a stronger prognostic variable compared to microsatellite instability or 18q allelic loss in patients with stages II and III colon cancer
Halling, Kevin C. , French, A. J. , Burgart, Lawrence J., Foster, Nathan R. , Goldberg, Richard M. , Thibodeau, Stephen N. , Sinicrope, Frank A. , Sargent, Daniel J. , O’Connell, M. J., Witzig, Thomas E.

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 9523-9523

10.1200/jco.2005.23.16_suppl.9523 Get It